Skip to main navigation Skip to search Skip to main content

AZURE-Outcomes: A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High R

Grants and Contracts Details

StatusActive
Effective start/end date9/21/26 → 9/21/28

Funding

  • AstraZeneca Pharmaceuticals LP (domestic): $2.00